Granules India Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
GRANULES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Granules India reported Q1 FY26 consolidated revenue from operations of Rs 12,101 million, up about 2.6% from Rs 11,798 million in Q1 FY25. Consolidated profit after tax fell to Rs 1,126 million from Rs 1,346 million a year ago, a decline of around 16%, with EPS at Rs 4.64 versus Rs 5.56. Standalone numbers were weaker, with revenue down roughly 5% to Rs 8,102 million and PAT down about 26% to Rs 695 million. The company booked a net exceptional loss of Rs 259 million in the quarter, covering Rs 121.6 million in transaction costs for the Senn Chemicals AG acquisition, settlements of prior GPI litigations (earlier treated as contingent liabilities), partly offset by a Rs 104 million gain on disposal of an old US Pharma investment. Senn Chemicals AG (Switzerland) has been consolidated from April 10, 2025. The Gagillapur facility remains under a USFDA warning letter (received Feb 2025), with manufacturing paused since Sept 2024, continuing to weigh on revenue and costs. The auditor (S.R. Batliboi & Associates LLP) issued a clean limited review with no qualifications.
Mixed for shareholders – top line grew modestly on consolidation, but profitability slipped year-on-year, especially on a standalone basis, dragged by USFDA-related production issues and acquisition costs. Watch the Gagillapur remediation progress and the contribution from the new Senn Chemicals acquisition in coming quarters to gauge a recovery.